"The
Report PharmaPoint: Multiple Sclerosis - Global Drug Forecast and
Market Analysis to 2024 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
Multiple
Sclerosis (MS) is an inflammatory autoimmune disease of the central
nervous system which leads to neurological disability. The exact
underlying cause of the disease is poorly understood; however, it
appears to involve a complex combination of genetic susceptibility
and a non-genetic trigger. The MS therapeutics market has entered an
exciting phase, with an upsurge of available treatment options. Over
the forecast period, patients are expected to continue to switch to
the oral disease-modifying therapies (DMTs), lessening the stronghold
of the established injectable treatments. There are also several
promising products in the late-stage pipeline, with a diverse range
of mechanisms offering clinical advantages intended to address unmet
needs. Both pipeline and marketed DMTs are seeking approval for the
treatment of progressive MS, which currently represents a significant
unmet need. These factors are expected to increase treatment rates
throughout the 10MM resulting, driving market growth. However, this
will be largely offset by brand erosion due to the emergence of
biosimilars and generic small molecules.
View Report At
:http://www.marketresearchreports.biz/analysis/491293
Highlights
Key Questions Answered
-
The MS market has experienced a paradigm shift with the launch of
first-line oral DMTs and efficacious escalation therapies. In light
of this, what are the current clinical and environmental unmet needs?
Will there be opportunities in this market for drug developers
throughout the forecast period?
-
The current late-stage MS pipeline is robust and diverse, with 13
products in Phase III. GlobalData has profiled nine DMT drug
therapies, of which eight are anticipated to launch during the
forecast period. What impact will these drugs have on the market? How
will they affect the treatment algorithm for MS? Will these drugs
fulfil any of the unmet needs for MS?
-
The diagnosis and management of MS is challenging, even for the most
experienced neurologists. How does the diagnosis and management of MS
differ amongst the 10MM? Which DMT treatments are most commonly
prescribed in each market, and how will prescribing patterns change
over the forecast period?
Key Findings
-
The main driver of growth in the MS market will be the introduction
of novel DMT products over the forecast period. Drugs targeting
clinical unmet needs; such as improved efficacy, more convenient
administration, or progressive MS approval; will increase treatment
rates and drive market growth.
-
There is a high disparity between treatments for RRMS and progressive
MS amongst the currently available drugs and, despite its diversity,
the late late-stage pipeline remains skewed towards RRMS. As such,
the RRMS market will become increasingly competitive making it more
difficult for new entrants to gain patient share.
-
The biggest barrier for growth in the MS market will be competition
from generic/biosimilar products for key branded therapies. In
particular, the launch of generic small-molecules will hamper future
growth of the MS market.
-
Considerable opportunity remains for products that meet the unmet
needs in the MS market. A drug that prevents disease progression and
the accumulation of disability would be viewed favourably.
Additionally, targeting progressive MS will be an ongoing
opportunity.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/491293
Scope
- Overview of MS, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
treatment guidelines.
- Annualized MS market revenue,
annual cost of therapy and treatment usage pattern data from 2014 and
forecast for ten years to 2024.
- Key topics covered include
market characterization, unmet needs, R&D and clinical trials
assessment, late stage clinical trial analysis and implications for
the MS therapeutics market.
- Pipeline analysis: focus on
nine late-stage pipeline MS drugs, discussing emerging trends as well
as an overview of earlier phase drugs and a top-line analysis of
therapeutic vaccines.
- Analysis of the current and
future market competition in the global MS therapeutics market.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
- Develop business strategies
by understanding the trends shaping and driving the global MS
therapeutics market.
- Drive revenues by
understanding the key trends, innovative products and technologies,
market segments, and companies likely to impact the global MS
therapeutics market in future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analysing the performance of various competitors.
- Identify emerging players
with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the
global MS therapeutics market from 2014-2024.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
3 Disease Overview 27
3.1 Etiology and
Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 28
3.2 Classification 29
3.2.1 Relapse-Remitting
Multiple Sclerosis 29
3.2.2 Secondary Progressive
Multiple Sclerosis 30
3.2.3 Primary Progressive
Multiple Sclerosis 30
3.2.4 Progressive Relapsing
Multiple Sclerosis 30
3.3 Symptoms 31
3.4 Prognosis 32
3.5 Quality of Life 33
4 Epidemiology 34
4.1 Disease Background 34
4.2 Risk Factors and
Comorbidities 35
4.2.1 Family members of MS
patients have a 1-5% risk of developing MS 36
4.2.2 Women are twice as likely
to develop MS, but men have a worse prognosis 37
4.2.3 Caucasians have a higher
risk of MS than any other race/ethnicity 37
4.2.4 Protective effect of
vitamin D on MS may relate to latitude and month of birth 37
4.2.5 Timing of environmental
exposures affects MS risk 38
4.2.6 Exposure to smoking may
increase MS risk and worsen prognosis 38
4.2.7 Autoimmune Disease
Comorbidities of MS 39
4.2.8 Mental comorbidities are
found in up to 60% of MS patients and may affect relapse rates 39
4.3 Global Trends 40
4.3.1 North America 40
4.3.2 Europe 41
4.3.3 Asia 41
4.4 Forecast Methodology 42
4.4.1 Sources Used 45
4.4.2 Sources Not Used 51
4.4.3 Forecast Assumptions and
Methods 51
4.5 Epidemiological Forecast of
Multiple Sclerosis (2014-2024) 58
4.5.1 Diagnosed Prevalent Cases
of MS 58
4.5.2 Age-Specific Diagnosed
Prevalent Cases of MS 60
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment